输尿管结石药物排石治疗:未来趋势与知识空白
本文通过检索MEDLINE和Cochrane图书馆截至2018年10月28日的文献,筛选524篇文章后纳入69篇,综述输尿管结石药物排石治疗(MET)的价值与未来方向。高质量随机双盲安慰剂对照试验多数未发现MET提高排石率,与受低质量试验影响的Meta分析结果矛盾。作者认为MET获益证据强度低,即使对>5 mm远端输尿管结石也是如此。
要点
- 高质量随机双盲安慰剂对照试验多数未发现MET提高输尿管结石排石率。
- Meta分析结果受低质量试验影响,与高质量单试验结果不一致。
- α受体阻滞剂作为MET可能在部分经充分告知的大结石患者中保留作用。
核心结论
- MET对输尿管结石获益的证据强度低,即使对>5 mm的远端输尿管结石也是如此。
- 在缺乏进一步高质量数据的情况下,每位临床医生需自行决定相信高质量单试验还是Meta分析。
研究设计与样本
- 文献综述:检索MEDLINE数据库和Cochrane图书馆,收集截至2018年10月28日发表的输尿管结石MET相关文章。
- 共筛选524篇文章,选取69篇符合纳入标准的文献。
- 在以结石清除为主要结局的MET原始研究中,7篇符合Cochrane协作组随机试验偏倚风险评估工具的高质量要求。
主要发现
- 绝大多数无高偏倚风险或不明确偏倚风险的随机双盲安慰剂对照试验未发现MET增加输尿管结石排石率的获益。
- Meta分析结果显示MET有获益,但该结果受低质量试验影响而偏倚。
- 患者摘要指出各研究结局不一,临床医生需自行决定相信哪些研究。
临床怎么用
- α受体阻滞剂作为MET可能在经充分告知、了解副作用和超说明书使用的大结石患者中选择性保留作用。
- 在缺乏进一步高质量数据的情况下,临床医生需自行决定相信高质量单试验还是Meta分析。
局限性
- MET获益的证据强度低,即使对>5 mm的远端输尿管结石也是如此。
- 在缺乏进一步高质量数据的情况下,临床医生需自行决定相信高质量单试验还是Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Medical expulsive therapy (MET) for ureteral stones has become a controversial area due to the contradictory results of high-quality trials and meta-analyses. OBJECTIVE: We aimed to review the literature to evaluate the value of and future directions for MET for ureteral stone disease. EVIDENCE ACQUISITION: A literature search of the MEDLINE database and the Cochrane Library was conducted to collect articles about MET for ureteral calculi published up to 28 October 2018. A total of 524 articles were screened. Sixty-nine publications that met the inclusion criteria for this review were chosen. Among the primary research articles on MET with stone clearance as the primary outcome, seven responded to high-quality requirements of Cochrane Collaboration's tool for assessing the risk of bias in randomised trials. EVIDENCE SYNTHESIS: The vast majority of randomised, double-blind, placebo-controlled trials without a high or an unclear risk of bias did not find a benefit of MET for increased ureteral stone passage rates. This is in contrast to results of meta-analyses that are skewed by low-quality trials. CONCLUSIONS: The strength of evidence for the benefit of MET in ureteral stones is low, even for distal ureteral stones >5 mm. In the absence of further high-quality data, individual clinicians are required to decide for themselves whether to believe high-quality single trials or meta-analyses. PATIENT SUMMARY: We evaluated the value of and future directions for medical expulsive therapy (MET) for ureteral stone disease. We found that outcomes varied between studies. Individual clinicians are required to decide for themselves which studies to believe. Alpha-blockers as MET may retain a role in a selective group of well-counselled patients with larger stones who understand the side effects and off-label use.
引用
- De Coninck V, Antonelli J, Chew B, et al. Medical Expulsive Therapy for Urinary Stones: Future Trends and Knowledge Gaps. Eur Urol. 2019. PMID: 31421941. doi:10.1016/j.eururo.2019.07.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。